TxCell is a biotechnology company that develops platforms for innovative, personalized T cell immunotherapies for the treatment of severe inflammatory and autoimmune diseases with high unmet medical need.

TxCell targets a wide range of inflammatory diseases (both T-cell and B-cell-mediated) including Crohn’s disease, lupus nephritis, bullous pemphigoid and multiple sclerosis, as well as transplantation-related inflammatory disorders.

TxCell is the only clinical-stage cellular therapy company fully dedicated to the science of regulatory T lymphocytes (Tregs).

Tregs represent a recently discovered T cell population for which anti-inflammatory and immunosuppressive properties have been demonstrated.

Contrary to conventional approaches based on non-specific polyclonal Tregs, TxCell is exclusively developing antigen-specific Tregs.

This antigen specificity may either come from genetic modifications with a Chimeric Antigen Receptor (CAR) or from pre-existing Treg T-Cell Receptor (TCR).

TxCell is developing two proprietary technology platforms, ENTrIA, which is composed of genetically-engineered Tregs, and ASTrIA, which is composed of non-modified naturally antigen-specific Tregs.

  • TxCell is based in Sophia-Antipolis, France
  • TxCell is listed on Euronext Paris